Raymond James Cuts Regeneron Price Target: Eylea HD Falls Short of Expectations

Raymond James has revised its stock price target for Regeneron Pharmaceuticals (REGN) downward, citing the company's failure to meet sales targets for its eye disease treatment Eylea HD. This has heightened concerns about Regeneron's short-term growth prospects. Analysts noted that Eylea HD's market performance falling below expectations could negatively impact the company's revenue projections. Consequently, Raymond James lowered its 12-month price target for Regeneron, advising investors to exercise caution. Regeneron is also known for its other drug portfolio alongside Eylea HD. However, the product's inability to meet expectations has raised questions about the company's overall financial health. Raymond James' report is seen as a step toward reassessing Regeneron's position, particularly in the competitive pharmaceutical market. Investors will closely monitor Regeneron's next steps to boost Eylea HD sales and the performance of its other products. Raymond James' revision reflects a cautious stance on the company's near-term outlook. This is not investment advice.